CAR T‐cell therapy for pancreatic cancer

Chimeric antigen receptor (CAR) T‐cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology Jg. 116; H. 1; S. 63 - 74
Hauptverfasser:	DeSelm, Carl J., Tano, Zachary E., Varghese, Anna M., Adusumilli, Prasad S.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Wiley Subscription Services, Inc 01.07.2017
Schlagworte:	adoptive cell therapy Antigens, Neoplasm - immunology Cancer surgery CAR T cells Carcinoembryonic Antigen - immunology CD24 Antigen - immunology checkpoint blockade chimeric antigen receptor Clinical Trials as Topic GPI-Linked Proteins - immunology Humans immunotherapy Immunotherapy, Adoptive Mesothelin Mucin-1 - immunology Neoplasm Proteins - immunology Pancreatic cancer Pancreatic Neoplasms - immunology Pancreatic Neoplasms - therapy Receptor, ErbB-2 - immunology Receptors, Antigen, T-Cell Receptors, Natural Killer Cell - immunology Stromal Cells - immunology T-Lymphocytes - immunology T-Lymphocytes - transplantation Transplantation Conditioning checkpoint blockade chimeric antigen receptor CAR T cells adoptive cell therapy immunotherapy
ISSN:	0022-4790, 1096-9098, 1096-9098
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!